How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,019 results for

"covid 19" OR "novel coronavirus"

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. The effects and safety of lopinavir combined with ritonavir for novel coronavirus (COVID-19) pneumonia: a systematic review and meta-analysis

The effects and safety of lopinavir combined with ritonavir for novel coronavirus (COVID-19) pneumonia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

42. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of observational studies

Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

43. Clinical features and imaging findings of novel coronavirus pneumonia (COVID-19), a systematic review and meta-analysis

Clinical features and imaging findings of novel coronavirus pneumonia (COVID-19), a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

44. Clinical practice guidelines of traditional Chinese herbal medicine for novel coronavirus(COVID-19): a systematic review

Clinical practice guidelines of traditional Chinese herbal medicine for novel coronavirus(COVID-19): a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

45. Efficacy and safety of Favipiravir compared with other treatments for novel coronavirus (COVID-19)

Efficacy and safety of Favipiravir compared with other treatments for novel coronavirus (COVID-19) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2020 PROSPERO

46. The efficacy and safety of tested treatments for novel coronavirus pneumonia (COVID-19): a systematic review and network meta-analysis clinical trials

The efficacy and safety of tested treatments for novel coronavirus pneumonia (COVID-19): a systematic review and network meta-analysis clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

47. Efficacy and safety of ribavirin in the treatment of novel coronavirus (COVID-19) pneumonia: a systematic review and meta-analysis

Efficacy and safety of ribavirin in the treatment of novel coronavirus (COVID-19) pneumonia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2020 PROSPERO

48. Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19) in rehabilitation period: a systematic review and meta-analysis

Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19) in rehabilitation period: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

49. Chloroquine combined with azithromycin for novel coronavirus (COVID-19) pneumonia: a systematic review and meta-analysis of randomised controlled trials

Chloroquine combined with azithromycin for novel coronavirus (COVID-19) pneumonia: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

50. Complementary and alternate therapies (CAM) for treating novel coronavirus (COVID-19): a systematic review and meta-analysis

Complementary and alternate therapies (CAM) for treating novel coronavirus (COVID-19): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

51. Blood coagulation in severe 2019 novel coronavirus disease (COVID-19) patients: a meta-analysis and systematic review

Blood coagulation in severe 2019 novel coronavirus disease (COVID-19) patients: a meta-analysis and systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2020 PROSPERO

52. The diagnostic accuracy of saliva in detecting novel coronavirus in symptomatic or asymptomatic people at risk of COVID-19 exposure - A systematic review and meta-analysis

The diagnostic accuracy of saliva in detecting novel coronavirus in symptomatic or asymptomatic people at risk of COVID-19 exposure - A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

53. Mixed Chinese herbs and Western medicine for novel coronavirus disease 2019 (COVID-19): a mixed-methods review

Mixed Chinese herbs and Western medicine for novel coronavirus disease 2019 (COVID-19): a mixed-methods review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

54. Prevalence and correlation of symptoms and comorbidities in the novel coronavirus (COVID-19): a systematic review and meta-analysis of the infected patients

Prevalence and correlation of symptoms and comorbidities in the novel coronavirus (COVID-19): a systematic review and meta-analysis of the infected patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

55. Estimation of novel coronavirus (COVID-19) basic reproductive number and case fatality rate: insights from a systematic review and meta-analysis

Estimation of novel coronavirus (COVID-19) basic reproductive number and case fatality rate: insights from a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

56. Efficacy of acupuncture and moxibustion in adjuvant treatment of patients with novel coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Efficacy of acupuncture and moxibustion in adjuvant treatment of patients with novel coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

57. D-dimer, Disease Severity and Deaths (3D-Study) in Novel Coronavirus Disease (COVID-19): A Systematic Review and Meta-analysis

D-dimer, Disease Severity and Deaths (3D-Study) in Novel Coronavirus Disease (COVID-19): A Systematic Review and Meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

58. A systematic review about a rehabilitation therapist, what can we do to help patients with novel coronavirus (COVID-19) pneumonia?

A systematic review about a rehabilitation therapist, what can we do to help patients with novel coronavirus (COVID-19) pneumonia? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2020 PROSPERO

59. COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19

COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 Evidence summary Published: 5 June 2020 www.nice.org.uk/guidance/es27 pathways Key messages Key messages The content of this evidence review was up-to-date on 4 June 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA (...) or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy COVID-19 manifests as a predominantly respiratory illness, of widely varying clinical severity. At the most severe end of the spectrum it results in severe pneumonia and respiratory failure with the need for mechanical ventilation. Acute respiratory distress syndrome (ARDS) is often a pre- terminal event in patients with COVID-19 and is the leading cause of mortality

2020 National Institute for Health and Clinical Excellence - Advice

60. COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19

COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 Evidence summary Published: 21 May 2020 www.nice.org.uk/guidance/es24 pathways Key messages Key messages The content of this evidence review was up-to-date on 1 April 2020. See (...) roles in COVID-19: © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 3• Coronaviruses, including those responsible for Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and coronavirus disease (COVID-19), bind to ACE2 to gain access to the epithelial cells. Therefore, upregulation of ACE2 could theoretically increase a person's risk of COVID-19 or developing more severe COVID-19

2020 National Institute for Health and Clinical Excellence - Advice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>